A Phase 1, Open-Label Study of Latanoprost Acid Plasma Concentrations in Pediatric and Adult Glaucoma Patients Treated With Latanoprost.

Completed · Phase 1

Conditions studied: Glaucoma, Ocular Hypertension

In brief

To evaluate the steady-state systemic plasma concentrations of latanoprost acid following administration of latanoprost 0.005% (1.5 ug) in pediatric and adult subjects with glaucoma or ocular hypertension.

Key facts

Study ID
NCT00638742
Run by
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
People needed
47
Starts
2008-05-01
Expected to finish
2009-03-01
Last updated by the study team
2021-02-02

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.